Clinical Trial

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

Study acronym: NIPIRESCUE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
NIPIRESCUE evaluates nivolumab and ipilimumab in patients with MSI/dMMR mCRC resistant to anti-PD1 monotherapy and previously treated with fluoropyrimidine, oxaliplatine, irinotecan, and anti- vascular endothelial growth factor (VEGF) or anti- epidermal growth factor receptor (EGFR) therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-04-04; most recent amendment 2025-06-26.
Status change: Not Yet Recruiting → Recruiting 2022-05-06
Trial Details
NCT Number NCT05310643
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions Metastatic Colorectal Cancer
Enrollment 30 participants
Start Date 2022-05-05
Primary Completion 2025-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-07-01